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Abstract
Background: Palmar hyperlinearity is a feature of ichthyosis vulgaris, the monogenic 
skin disorder caused by FLG loss- of- function mutations.
Objective: To investigate how well the presence or absence of hyperlinear palms 
(HLP) detect FLG genotype in children.
Methods: STARD criteria are used to report this diagnostic accuracy study. Phenotype 
and genotype data (four most prevalent FLG null mutations) were obtained from a 
total of 3656 children in three studies: the UK CLOTHES trial (children 1– 5 years with 
moderate– severe atopic eczema); UK BEEP trial (2 year olds at high risk of developing 
atopic eczema); UK- Irish eczema case collection (0– 16 year olds with atopic eczema). 
All participants included in analyses of HLP as the index test and FLG genotype as the 
reference were of white European ancestry.
Results: Thirty- two percent of participants (1159/3656) had FLG null mutation(s) and 
37% (1347/3656) had HLP. In 13% (464/3656), HLP was recorded as ‘unsure’ or not 
recorded. The sensitivity and specificity of HLP for detecting FLG mutations in each 
of the studies was: 67% (95% CI 55– 78%) and 75% (67– 82%) in CLOTHES; 46% (36– 
55%) and 89% (86– 91%) in BEEP; 72% (68– 75%) and 60% (57– 62%) in the UK- Irish 
case collection. Positive and negative likelihood ratios were: 2.73 (1.95– 3.81) and 0.44 
(0.31– 0.62) in CLOTHES; 4.02 (2.99– 5.40) and 0.61 (0.52– 0.73) in BEEP; 1.79 (1.66– 
1.93) and 0.47 (0.42– 0.53) in the UK- Irish collection.
Discussion: Trained observers were able to define palmar hyperlinearity in the major-
ity (3191/3656, 87%) of cases. The presence of HLP is not a reliable sign to detect 
FLG mutations, but the absence of HLP excludes FLG null genotype with a reasonable 
degree of certainty.
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1  |  INTRODUC TION
Palmoplantar hyperlinearity, keratosis pilaris and ichthyosis are fea-
tures of ichthyosis vulgaris (MIM #146700) caused by loss- of- function 
(null) mutations in the gene encoding filaggrin (FLG).1 FLG null muta-
tions are semi- dominant, meaning individuals with one mutation have 
a mild phenotype and individuals with two null mutations have more 
severe ichthyosis. Palmar hyperlinearity was the clinical feature most 
strongly associated with FLG null genotype in a population- based 
study of children aged 7– 9 years (heterozygote odds ratio 19.3 (95% 
confidence interval 11.7– 31.7))2 but hyperlinearity can also occur in 
FLG wild- type individuals (those with no FLG mutations).2
In addition to causing the monogenic dry skin condition of ich-
thyosis vulgaris, FLG null mutations also increase risk of the common 
complex trait atopic eczema.3 The strongest and most highly signif-
icant effect of FLG null genotype on eczema risk is present in early- 
onset, persistent and severe disease4 associated with multiple other 
atopic conditions, including asthma and food allergy.5- 7 FLG hap-
loinsufficiency is believed to contribute to the pathophysiology of 
atopic disease by multiple mechanisms in the biochemical, physical 
and microbial components of skin barrier formation and function.8 
The mechanisms by which FLG null genotype leads to palmoplantar 
hyperlinearity remain unknown.
Filaggrin deficiency has been targeted therapeutically using 
emollients containing filaggrin's constituent amino acids9 and obser-
vational studies have reported differences in patient response to im-
munosuppressive treatment based on FLG genotype.10 Knowledge 
of an eczema patient's FLG genotype could therefore be used for 
current and future personalized medicine strategies, but genotyping 
is not yet available in routine clinical practice.
We sought to test the hypothesis that examination for the clin-
ical feature of hyperlinear palms (HLP) can be used as a proxy for 
FLG null genotype (having one or two loss- of- function mutations) in 
children with eczema or at high risk of atopic eczema.
2  |  METHODS
This study was conducted using all available data from three pae-
diatric eczema studies: the CLOTHES trial of silk clothing which re-
cruited 300 children aged 1– 5 years with moderate– severe atopic 
eczema11; the BEEP study, which studied 1394 infants at high risk 
of atopic eczema based on family history, up to 2 years of age12; 
and a UK- Irish case collection which recruited 4053 children aged 
0– 16 years with doctor- diagnosed atopic eczema from secondary 
and tertiary care in the Republic of Ireland, Scotland, England and 
Northern Ireland.5,13,14 The presence or absence of HLP or ‘unsure’ 
was recorded by research nurses in the CLOTHES and BEEP stud-
ies and medical doctors in the UK- Irish case collection. Research 
nurses received training in the observation of HLP using clinical 
photographs of the palmar aspects of children's hands, including 
paediatric ichthyosis vulgaris cases. The teaching material is shown 
G R A P H I C A L  A B S T R A C T
Palmar hyperlinearity is associated with FLG loss- of- function 
mutations. This diagnostic test accuracy study used data previously 
collected as part of three paediatric cohorts, including a total of 
3656 children. We aimed to investigate whether the presence 
or absence of hyperlinear palms (HLP) could be used to detect 
FLG genotype in children. Thirty- two percent of participants 
(1159/3656) had FLG null mutation(s) and 37% (1347/3656) had 
HLP. The presence of HLP was not a reliable clinical sign for the 
detection of FLG mutations.
Key Messages
• Examination for palmar hyperlinearity is not a sensitive 
or specific way to detect filaggrin mutations
• However, the absence of HLP can be used to exclude 
FLG haploinsufficiency with reasonable certainty
• This study focused on people of white European ethnic-
ity; other ethnic groups require further work
F I G U R E  1  Patterns of palmer 
hyperlinearity recorded in the UK- Irish 
case collection. Clinical appearance of 
Vertical (A), Horizontal (B) and Crosshatch 
(C) HLP patterns as previously reported by 
Brown et al.2 CC Hand by HeadsOfBirds 
from the Noun Project
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in the Supplementary material. Severity and patterns2 (Figure 1) of 
hyperlinearity were recorded in the UK- Irish case collection only. 
The clinicians and trained observers recording HLP were unaware of 
the participants’ genotypes and similarly the laboratory staff carry-
ing out genetic analysis did not have access to the phenotypic data.
Individuals had been genotyped for the four most prevalent FLG 
null mutations (R501X, 2282del4, R2447X and S3247X) as part of 
the previous studies.5,11- 14 Individuals with one or two FLG null mu-
tations (heterozygotes, homozygotes and compound heterozygotes) 
were considered as one group for this analysis, to be compared with 
the group of individuals with FLG wild- type genotype (having no 
mutations). Characteristics of the study participants are shown in 
Table 1. Individuals of white European ethnicity were selected be-
cause of knowledge about the prevalent FLG mutations in this pop-
ulation group.15 All the participants in this study (or their parents or 
guardians) had given written informed consent as part of the original 
study consent process for their data and DNA from blood or saliva 
to be used for future research.1,11,12
The utility of HLP (assessed as yes or no) as a proxy for FLG null 
genotype was reviewed using cross- tabulation and investigated 
by calculation of sensitivity, specificity, likelihood ratios, diagnos-
tic odds ratios, positive and negative predictive values for each 
study and presented with 95% confidence intervals. For the BEEP 
study, this was repeated for the subset of children with eczema at 
24 months old. The cases where HLP were assessed as unsure were 
included in a sensitivity analysis as no HLP. We have reported this 
diagnostic accuracy study, in which the presence/absence of HLP 
is the index test and FLG genotype is the reference standard, using 
STARD criteria.16 These analyses were not pre- specified in the orig-
inal study protocols.





UK- Irish case collection
(n = 2623)
Age in years
Mean (SD) 4.9 [3.6] Randomized just after birth; HLP 
assessed up to 2 years
4.0 [4.1]
0.5, 18Min, max 1, 15
Sex
Male 124 (57%) 432 (53%) 1630 (62%)
Female 93 (43%) 384 (47%) 992 (38%)
Missing data - - 1
Eczema at 24 monthsa
no - 217 (100%) 627 (77%) - 2623 (100%)
yes 189 (23%)
Eczema severity scores
EASI b EASI assessed at recruitment b EASI assessed at24 months of ageb Not done
Mean (SD) 10.1 (8.8) 0.7 (1.8)
Median (IQR) 6.8 (4– 13.6) 0 (0 to 0.6)
Min, max 1, 46 0, 20.5
n 217 812
Patient Orientated Eczema 
Measurec
At recruitment At 24 months of age Not done
Mean (SD) 16.9 (5.1) 1.8 (3.8)
Min, max 5, 28 0, 26
n 217 814
Nottingham Eczema Severity 
Score (NESS) d
At recruitment Not done At recruitment
Mean (SD) 13 (1.6) 11 (2.8)
Min, max 9, 15 3, 15
n 217 2613
Abbreviations: IQR, interquartile range; SD, standard deviation.
aDiagnosed using UK Working Party criteria.20
bEczema Area and Severity Index.21
cPOEM.22
dNottingham Eczema Severity Score.23
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3  |  RESULTS
Phenotype and genotype data were available for a total of 3656 chil-
dren of white European ethnicity, including 217 from the CLOTHES 
study, 2623 from the UK- Irish case collection and 816 from the BEEP 
study (Figure 2). The prevalence of FLG null mutations varied from 
15% (125/816) in BEEP to 37% (960/2623) in the UK- Irish eczema 
case collection (Table 2). The prevalence of HLP varied from 15% 
(124/816) in BEEP to 44% (1142/2623) in the UK- Irish collection 
(Table 2). HLP was recorded as ‘unsure’ or not recorded in 13% of 
the total combined study population, but 15% in the UK- Irish collec-
tion (395/2623) (Table 2).
Cross- tabulation of FLG genotype by HLP in Table 3 shows that 
HLP are observed in children with and without FLG null mutations in 
each of the three studies. Table 4 shows the sensitivity, specificity, 
likelihood ratios, diagnostic odds ratio and predictive values of HLP 
for FLG genotype in each study. Results varied according to the con-
text. Participants in the CLOTHES study and UK- Irish case collec-
tion have established atopic eczema (moderate– severe in CLOTHES; 
mild, moderate and severe in the UK- Irish collection). In these stud-
ies, the sensitivity and specificity of HLP for FLG null genotype are 
estimated to be 67% and 72% sensitivity, 75% and 60% specificity 
respectively (Table 4). In contrast, in the BEEP study, which com-
prised young children at high risk for atopic eczema, the sensitivity 
of HLP was only ~46% but the specificity was ~89%. Similar sensi-
tivity and specificity were observed in BEEP in the subset of children 
who had developed eczema by 24 months of age. Figure 3 displays 
the sensitivity and specificity for each study.
The positive likelihood ratios in Table 4 compare the probability 
that HLP is present in a child with FLG null genotype compared to 
F I G U R E  2  Flow diagram showing 
recruitment, exclusions and reasons for 
missing data. aChild too distressed, child 
declined, parents changed their minds, 
participant did not attend any follow- up 
visits and consent withdrawn from clinical 
trial. bEither visit not done face to face or 
sample not collected at visit and either 
the kit was not left or the parents did not 
return sample
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the probability of HLP in a child without FLG null genotype. Positive 
likelihood ratios can be used to assess how good HLP is as a potential 
test for identifying FLG mutations. In these three studies the positive 
likelihood ratios show that HLP are around twice as likely in children 
with a FLG null mutation compared to children who do not have a 
mutation.
The positive predictive value of HLP is determined in part by 
the prevalence of FLG null genotype. In the BEEP study population, 
where ~15% have FLG null mutations, the positive predictive value 
is only 41% (95% CI 32– 50%) whilst in CLOTHES, where 34% have 
FLG null mutations, the positive predictive value is 58% (47– 69%). 
In all three studies the negative predictive values were estimated 
to be ≥80%.
Additional sensitivity analysis was carried out to investigate the 
effect of including children for whom HLP were recorded as ‘unsure’ 
(Tables S1 and S2). Estimates of sensitivity were smaller when chil-
dren for whom HLP were recorded as ‘unsure’ were included. Other 
estimates of diagnostic performance were similar to the analysis in-
cluding HLP assessed as no/yes.
Severity and patterns of hyperlinearity were recorded in the UK- 
Irish case collection only. Of those with HLP, 489/1142 (43%) had 
mild hyperlinearity and 296 (26%) had marked HLP (Table 5). The 
most prevalent pattern was ‘crosshatch’ (Table 6, Figure 1C) as previ-
ously reported.2 The percentage of children with FLG null mutations 
increased with HLP severity, however, severity was not classified 
for 281 of the 1142 children assessed as having hyperlinear palms 
which, therefore, limits interpretation of a possible correlation be-
tween FLG genotype and HLP severity.









+/+ (no mutations) 143 (66%) 691 (85%) 1663 (63%)
+/− (one FLG null 
mutation)
51 (24%) 122 (15%) 733 (28%)
−/− (two FLG null 
mutations)
23 (11%) 3 (<0.5%) 221 (8%)
+/− or 
−/− (unsure)a
- - 6 (<0.5%)
At least one FLG null 
mutation
74 (34%) 125 (15%) 960 (37%)
Hyperlinear palms
No 127 (59%) 632 (77%) 1086 (41%)
Yes 81 (37%) 124 (15%) 1142 (44%)
Unsure 9 (4%) 56 (7%) 395 (15%)
Not assessed - 4 (<0.5%) - 
Severity of 
hyperlinearityb
Not done Not done
Normal - - 76 (3%)
Mild - - 489 (19%)
Marked - - 296 (11%)
Not known - - 263 (10%)
Missing - - 18 (1%)
Pattern of 
hyperlinearityb,c
Not done Not done
‘Vertical’ - - 116 (4%)
‘Horizontal’ - - 289 (11%)
‘Crosshatch’ - - 433 (17%)
Not applicable - - 41 (2%)
Unknown - - 263 (10%)
aIncomplete genotype results but included in this study because the 
results are sufficient to define ‘At least one FLG null mutation’.
bSeverity and pattern summarized for children assessed as having 
hyperlinear palms in the UK- Irish case collection.
cPatterns are shown in Supplementary Material, as previously 
reported.2





+/+ 104 34 138
+/− or −/− 23 47 70
127 81 208
BEEP study Hyperlinear palms
Total— all children No Yes
FLG genotype
+/+ 571 73 644
+/− or −/− 61 51 112
632 124 756
BEEP study Hyperlinear palms Total
— children with atopic eczema a No Yes
FLG genotype
+/+ 115 20 135






+/+ 864 578 1442
+/− or −/− 222 564 786
1086 1142 2228
Note: +/+ indicates no mutations (FLG wild- type genotype); +/− or −/− 
indicates an individual with at least one mutation (FLG heterozygous, 
homozygous or compound heterozygous for null mutations).
adiagnosis based on UK working party criteria at 24 months of age.
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4  |  DISCUSSION
4.1  |  Main findings
This analysis brings together three of the largest clinical studies in 
which HLP have been reported. Screening was performed for the 
four most common FLG null mutations in the study populations using 
well- established methodology.15,17 The presence or absence of HLP 
was recorded in 87% of children, indicating a degree of confidence 
in the trained observers. However, in the context of these paediatric 
studies HLP was not a reliable clinical sign for the detection of FLG 
null genotype. In contrast, our data show that the absence of HLP 
can be used to exclude FLG mutations with a reasonable degree of 
certainty (negative predictive value 80– 90%).
The prevalence of FLG null mutations detected in these three 
studies was in keeping with a high- risk population in the BEEP 
study (15%) and in children with a range of atopic eczema severi-
ties in the CLOTHES study and UK- Irish case collection (34– 35%). 
The prevalence of FLG null mutations affects the utility of HLP 
as a diagnostic test to some extent, as reflected in the positive 
and negative predictive values. It is important to note that if these 
findings are applied to an unselected population in which FLG mu-
tation prevalence is lower (e.g. Northern Europe where FLG muta-
tions are seen in <9% of people) the positive predictive value of 
HLP is likely to be <41%.
4.2  |  Strengths and limitations
A strength of this work is the opportunity to compare findings from 
three paediatric studies carried out for different purposes, giving 
complementary insights. Data from the pilot study conducted in 





children with atopic eczemaa UK- Irish case collection
Prevalence of FLG null 
mutation
70/208 (34%) 112/756 (15%) 39/174 (22%) 786/2228 (35%)
Sensitivity 67% (55% to 78%) 46% (36% to 55%) 49% (32% to 65%) 72% (68% to 75%)
Specificity 75% (67% to 82%) 89% (86% to 91%) 85% (78% to 91%) 60% (57% to 62%)
Positive likelihood ratio 2.73 (1.95 to 3.81) 4.02 (2.99 to 5.4) 3.29 (1.96 to 5.51) 1.79 (1.66 to 1.93)
Negative likelihood ratio 0.44 (0.31 to 0.62) 0.61 (0.52 to 0.73) 0.60 (0.44 to 0.82) 0.47 (0.42 to 0.53)
Diagnostic odds ratio 6.25 (3.33 to 11.72) 6.54 (4.2 to 10.19) 5.46 (2.51 to 11.93) 3.8 (3.15 to 4.58)
Positive predictive value 58% (47% to 69%) 41% (32% to 50%) 49% (32% to 65%) 49% (46% to 52%)
Negative predictive value 82% (74% to 88%) 90% (88% to 93%) 85% (78% to 91%) 80% (77% to 82%)
Note: 95% confidence intervals are shown in parentheses; note positive and negative predictive values depend on the prevalence of FLG null 
mutations. Children whose HLP status could not be determined were excluded from analysis.
adiagnosis based on UK working party criteria at 24 months of age.
F I G U R E  3  Forest plot showing sensitivity and specificity of HLP for detecting FLG status. CI, confidence interval; FN, false negative; FP, 
false positive; TN, true negative; TP, true positive
TA B L E  5  Relationship between severity of HLP and FLG genotype. (a) HLP severity and FLG genotype in all children (children assessed as 
not having hyperlinear palms are included in the normal category)
FLG genotype
Normal





(n = 489, 22%)
Marked
(n = 296, 13%)
Not known
(n = 263, 12%)
Missing
(n = 18, 1%)
+/+ 921 (79%) 303 (62%) 77 (26%) 136 (52%) 5 (28%) 1442 (65%)
+/− or −/− 241 (21%) 186 (38%) 219 (74%) 127 (48%) 13 (72%) 786 (35%)
Note: Data shown are for children in the UK- Irish case collection only. +/+ indicates no mutations (FLG wild- type genotype); +/− or −/− indicates an 
individual with at least one mutation (FLG heterozygous, homozygous or compound heterozygous for null mutations).
    |  1427BRADSHAW et Al.
preparation for BEEP18 were not included in our analysis because 
infants in the BEEP pilot were followed up to 6 months of age, and 
at this stage of development it is very difficult to distinguish palmo-
plantar hyperlinearity from physiological wrinkling of the neonatal 
palmar skin. This young age at recruitment may also have contrib-
uted to the higher proportion recorded as ‘unsure’ in the UK- Irish 
case collection.
Involvement of palmar skin is not common in infant eczema co-
horts and the presence or absence of palmar eczema was not specifi-
cally recorded; since eczema can cause a wrinkled appearance to the 
skin this is a minor potential confounding factor. A further important 
limitation is the restriction to participants of white European eth-
nicity. This was necessary to ascertain FLG null status by screening 
the four mutations which are most prevalent in the white European 
population and further work is required in populations of other 
ethnicities. More detailed FLG analysis, for example, using opti-
mized methods of next- generation sequencing to fully sequence the 
gene,19 might be useful to ascertain the full burden of FLG null muta-
tions and this might improve predictive value. However, it would also 
preclude current routine clinical use.
Additional limitations include the selection criteria required by 
recruitment to these clinical studies, meaning each is not an unse-
lected population. Furthermore, not all children recruited to these 
studies were able to be included, where consent was not given for 
a saliva sample, genotyping failed or not genotyped. These missing 
data meant the participants were excluded. However, the three 
studies provide new information on the value of HLP in the key 
populations in which the sign is most likely to be used: in those 
at high risk of developing eczema and in those who already have 
eczema. Given that clinical trial participants for new eczema treat-
ments are likely to be recruited from dermatology clinics, the ex-
ternal validity of the data from CLOTHES and the UK- Irish cohort 
is strong. Observers were allowed to record palmar hyperlinearity 
as ‘unsure’ or ‘unknown’ to optimize the reliability of any that were 
recorded present or absent, but the inter- observer variability in 
the observation of HLP has not been tested and this represents 
another potential limitation. Severe HLP are most highly predic-
tive of FLG null genotype (74% of children with severe HLP in the 
UK- Irish case collection had one/more FLG null mutations) but the 
assessment of severity and patterns of HLP each included sub-
stantial proportions of missing data (Tables 5 and 6) which limit the 
interpretation of these associations.
4.3  |  Clinical implications
Genetic analysis is likely to increase in availability in the future, but 
the use of bedside genetic testing is not yet available in routine clini-
cal practice. The ability to use HLP as a proxy for FLG genotype ap-
pears an attractive opportunity to utilize genetic knowledge without 
costly DNA analysis. However, our data show that HLP on clinical 
examination is not a useful surrogate for detecting FLG null muta-
tions. Conversely the absence of HLP can be used to exclude FLG 
haploinsufficiency with reasonable certainty. These studies were 
limited to people of white European ethnicity and further work is 
needed to study people of other ethnicities.
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(n = 116, 10%)
‘Horizontal’
(n = 289, 25%)
‘Crosshatch’
(n = 433, 38%)
NA
(n = 41, 4%)
Not known
(n = 263, 23%)
+/+ 60 (52%) 179 (62%) 179 (41%) 22 (54%) 138 (52%) 578 (51%)
+/− or −/− 56 (48%) 110 (38%) 254 (59%) 19 (46%) 125 (48%) 564 (49%)
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genotype); +/− or −/− indicates an individual with at least one mutation (FLG heterozygous, homozygous or compound heterozygous for null 
mutations); NA were individuals with HLP for whom a pattern was not recorded.
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